Infinity Pharmaceuticals Stock Price To Earnings To Growth
| INFIDelisted Stock | USD 0.13 0.01 7.14% |
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Price To Earnings To Growth Analysis
Infinity Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Infinity Pharmaceuticals Price To Earnings To Growth | (0.05) X |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Infinity Pharmaceuticals has a Price To Earnings To Growth of -0.05 times. This is 107.04% lower than that of the Biotechnology sector and 101.59% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 101.02% higher than that of the company.
Infinity Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Infinity Fundamentals
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.29 X | |||
| Revenue | 2.59 M | |||
| Gross Profit | (31.38 M) | |||
| EBITDA | (44.84 M) | |||
| Net Income | (44.37 M) | |||
| Cash And Equivalents | 56.58 M | |||
| Cash Per Share | 0.63 X | |||
| Total Debt | 917 K | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | (0.41) X | |||
| Cash Flow From Operations | (42.43 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.45) X | |||
| Price To Earnings To Growth | (0.05) X | |||
| Target Price | 0.3 | |||
| Number Of Employees | 30 | |||
| Beta | 1.38 | |||
| Market Capitalization | 2.63 M | |||
| Total Asset | 42.15 M | |||
| Retained Earnings | (855.95 M) | |||
| Working Capital | 26.67 M | |||
| Current Asset | 254.7 M | |||
| Current Liabilities | 70.06 M | |||
| Z Score | -29.4 | |||
| Net Asset | 42.15 M |
About Infinity Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |